Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report)’s stock price was down 5.5% during mid-day trading on Thursday. The company traded as low as $3.35 and last traded at $3.41. Approximately 435,719 shares traded hands during trading, an increase of 67% from the average daily volume of 261,100 shares. The stock had previously closed at $3.61.
Aadi Bioscience Stock Performance
The stock has a market cap of $86.93 million, a price-to-earnings ratio of -1.54 and a beta of 0.68. The business’s 50 day moving average is $4.28 and its 200-day moving average is $4.12.
About Aadi Bioscience
Aadi Bioscience, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for genetically defined cancers. The company’s primary product is FYARRO, an albumin-bound formulation of sirolimus designed to deliver the mTOR inhibitor to tumors.
FYARRO is approved by the U.S. Food and Drug Administration for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare type of soft-tissue cancer.
Recommended Stories
- Five stocks we like better than Aadi Bioscience
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
- Is Synopsys Back from the Dead? EDA Leader Inks Deals With Amazon and OpenAI
- MarketBeat Week in Review – 10/05 – 10/09
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
